About Wavelength Pharmaceuticals
Wavelength Pharmaceuticals is a Healthcare company based in Petah Tikva (Israel) founded in 1987, and was acquired by SK Capital in November 2017. APIs and finished dosage forms are manufactured for therapeutic categories. The company has 39 employees. Wavelength Pharmaceuticals has completed 1 acquisition, including Vanamali Organics. Its Indian entity Monolom India Pharma Private Limited reported revenue of ₹18.17 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides.
Company details
Wavelength Pharmaceuticals was founded in 1987 and is located in Petah Tikva, Israel. Active pharmaceutical ingredients and finished dosage forms are produced, including semi-solid topicals, transdermals, parenteral solutions, oral solids, and liquids. Therapeutic areas covered include oncology, allergic rhinitis, neurological disorders, and antihyperlipidemic treatments. Ongoing developments focus on antiepileptic, dermatological, and respiratory products within the pharmaceutical sector.
- Headquarters Petah Tikva, Israel
- Employees 39
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website wavelengthpharma.com
- Social LinkedIn Facebook
- Acquired by SK Capital (Nov 2017)
- Legal Name Monolom India Pharma Private Limited
- Date of Incorporation 27 Oct, 2017
- Jurisdiction Pune, Maharashtra, India
- Indian entity revenue₹18.17 Cr
FY 2025 · -1% YoY
- Indian entity net profit₹2.04 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹4.45 Cr
FY 2025 · 24% margin
- Investors
- Employee Count39
- Investments & Acquisitions
- Acquired bySK Capital
(Nov 2017)
Associated legal entities of Wavelength Pharmaceuticals
Wavelength Pharmaceuticals operates through Monolom India Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Monolom India Pharma Private Limited CIN U24303PN2017FTC188118 | Active | 27 Oct 2017 | Pune, Maharashtra | ₹18.2 Cr | 39 | 4 | View details |
Investors in Wavelength Pharmaceuticals
Wavelength Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include SK Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A global private investment firm focused on specialty sectors. | skcapitalpartners.com | New York, United States |
Investor details for Wavelength Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Monolom India Pharma Private Limited (Wavelength Pharmaceuticals)
Monolom India Pharma Private Limited is the primary company behind Wavelength Pharmaceuticals. The board of Monolom India Pharma Private Limited currently have 4 directors; the longest-serving is Ben Zion Dolitzky, appointed in 2023. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ben Zion Dolitzky DIN 10048697 | Director | 24 Mar 2023 | 3 yrs 7 mo | Monolom India Pharma Private Limited |
| Adrien Aymery Joel Bresson DIN 10859851 | Director | 22 Jan 2025 | 1 yr 9 mo | Monolom India Pharma Private Limited |
| Ashutosh Vijay Joshi DIN 11161084 | Director | 30 Jun 2025 | 1 yr 4 mo | Monolom India Pharma Private Limited |
| Chiara . Bergerone DIN 10240183 | Director | Monolom India Pharma Private Limited |
Financials of Wavelength Pharmaceuticals
Figures of Monolom India Pharma Private Limited, the primary company behind Wavelength Pharmaceuticals, for FY 2025. Revenue was ₹18.17 Cr (-1% year on year). Net profit was ₹2.04 Cr (11% margin). EBITDA was ₹4.45 Cr (24% margin). Revenue has grown at a compounded annual rate of +5% over three years and +10% over five years.
- ₹18.17 CrRevenue · FY 2025 · -1% YoY
- ₹2.04 CrNet profit · 11% margin
- ₹4.45 CrEBITDA · 24% margin
- ₹3.44 CrPaid-up capital
- 39Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Monolom India Pharma Private Limited are on its company page.
Detailed financial statements for Wavelength Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Wavelength Pharmaceuticals
Wavelength Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vanamali Organics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of research and development, process development, and manufacturing services | vanamaliorganics.com | Hyderabad, India | 2013 | Feb 2021 | •••• |
Complete acquisition details for Wavelength Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Wavelength Pharmaceuticals
3 dated milestones of Wavelength Pharmaceuticals across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Wavelength Pharmaceuticals is founded.
- Exit Acquired by SK Capital.
- Acquisition Acquires Vanamali Organics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Wavelength Pharmaceuticals
Complete news archive for Wavelength Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Wavelength Pharmaceuticals
Wavelength Pharmaceuticals was founded in 1987.
Wavelength Pharmaceuticals is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Wavelength Pharmaceuticals has 39 employees.
The primary company behind Wavelength Pharmaceuticals, Monolom India Pharma Private Limited, reported revenue of ₹18.17 Cr for FY 2025, down 1% year on year.
Wavelength Pharmaceuticals was founded in 1987 and is located in Petah Tikva, Israel. Active pharmaceutical ingredients and finished dosage forms are produced, including semi-solid topicals, transdermals, parenteral solutions, oral solids, and liquids. Therapeutic areas covered include oncology, allergic rhinitis, neurological disorders, and antihyperlipidemic treatments. Ongoing developments focus on antiepileptic, dermatological, and respiratory products within the pharmaceutical sector.
Wavelength Pharmaceuticals has made 1 acquisition, including Vanamali Organics.
Wavelength Pharmaceuticals has 1 investor. Key investors include SK Capital.
Wavelength Pharmaceuticals operates through Monolom India Pharma Private Limited.
Yes. Wavelength Pharmaceuticals was acquired by SK Capital in November 2017.
The legal entities of Wavelength Pharmaceuticals currently have 4 directors, including Chiara . Bergerone, Ben Zion Dolitzky, Ashutosh Vijay Joshi and others.